Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BOPA 2017 | Advancing cellular therapies for blood cancers

David Irvine • 6 Oct 2017
BOPA 2017
Lymphoma Non-Hodgkin Lymphoma

David Irvine from the Beatson Institute, Glasgow, UK outlines his presentation on cellular advances in hematological oncology given at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. Dr Irvine describes the areas of development and the associated challenges that have arisen in recent years.

More from David Irvine

Innovative new approaches required for the practical implementation of CAR T-cell therapy 2:48
Innovative new approaches required for the practical implementation of CAR T-cell therapy
David Irvine • 17 Nov 2018
CAR T-cell therapy: co-operation could lead to unprecedented levels of efficacy 2:08
CAR T-cell therapy: co-operation could lead to unprecedented levels of efficacy
David Irvine • 17 Nov 2018
Integrating cellular therapies into clinical practice 2:39
Integrating cellular therapies into clinical practice
David Irvine • 7 Oct 2017

Related Videos

Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL 3:25
Long-term follow-up of TRANSFORM: liso-cel versus SOC for R/R LBCL
Manali Kamdar • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals